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Niklas Lindegårdh4,5ˆAbstract
Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This
report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan
Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of
artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment.
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Artemisinin-based combination therapy (ACT) is recom-
mended by the World Health Organization as first-line
treatment of uncomplicated Plasmodium falciparum
malaria in sub-Saharan Africa [1]. The combination
comprises a fast-acting artemisinin derivative with rapid
effect on parasite clearance, and a long-acting drug to
prevent recrudescence and development of resistance.
The fixed-dose oral combination artemether-lumefantrine
(CoArtemW/RiametW, Novartis, Switzerland) is increasing-
ly used for treatment of P. falciparum malaria in travellers
returning to non-endemic areas, and is the first-line drug
for uncomplicated malaria at Karolinska University Hospi-
tal in Stockholm since 2010. The drug combination is also
recommended as follow-up treatment to artesunate in
patients recovering from severe P. falciparum malaria. The
present report describes artemether-lumefantrine treatment
failure in a traveller with P. falciparum malaria after
returning from Tanzania.* Correspondence: anna.farnert@ki.se
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A 57-year old man of Swedish descent presented at
Karo-linska University Hospital, on June 29, 2011, with a
one-day history of fever, chills, headache and loose stool,
two weeks after returning from Tanzania where he had
been working intermittently for a few years. He had dis-
continued atovaquone-proguanil chemoprophylaxis one
month before leaving endemic area. He reported being
previously healthy except an episode of necrotizing fasci-
itis in the left thigh six months earlier.
On examination, the patient had prominent chills
without any other clinical findings and C-reactive pro-
tein (CRP) was 166 mg/l, haemoglobin 171 g/l, platelet
72x109/l, bilirubin 33 μmol/l. He was started on intra-
venous cefotaxime and fluids for a suspected bacteremia,
and artemether-lumefantrine (20 mg/120 mg RiametW; 4
tablets per dose at 0, 8, 24, 36, 48 and 60 hours) was
prescribed after microscopy had shown 0.1% P.
falciparum infected erythrocytes. The first dose was
however delayed and parasitaemia peaked at 1.3% before
decreasing promptly during treatment (Figure 1). Due to
persistent fever and high CRP (369 mg/l) on the second
day, cefotaxime was changed to ceftazidime and a single
dose gentamicin for treatment of a potential concurrent
bacteraemia. The patient was discharged free of symp-
tom after five days and prescribed one week oralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Recrudescence of P. falciparum in a traveller treated with artemether-lumefantrine (RiametW, Novartis). The P. falciparum
parasitaemia (% infected erythrocytes as filled circles) decreased promptly after artemether-lumefantrine treatment was initiated (day 0) and
symptoms reappeared on day 21. The second episode was treated successfully with mefloquine. Plasma concentrations of artemether,
dihydroartemisinin, lumefantrine and desbutyl lumefantrine were assessed on day 6 and day 25. Lumefantrine concentrations (open triangles)
are shown in the graph whereas the other results are stated in the text.
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at and during admission were all negative. Malaria micros-
copy was negative at discharge as well as two days later.
On July 23 (24 days after treatment start), the patient
presented at the emergency room with high fever since
two-three days, jaundice, hypotension (systolic blood
pressure 80) and slightly impaired consciousness. He
responded promptly to intravenous fluids. CRP was
64 mg/l, hemoglobin 115 g/l, platelet count 116x109/l,
bilirubin 49 μmol/l, arterial blood gas and other tests
were normal. Blood films were again positive for P.
falciparum and oral mefloquine was started based on
0.4% parasitaemia estimated by the physician on call.
The initial parasitaemia was reevaluated to 2.6% by the
microbiology department the following day. The patient
recovered promptly and the mefloquine course was
completed. He was discharged three days after admis-
sion. On follow up one month later, the patient reported
no symptoms since discharge and microscopy of blood
films was negative for malaria parasites.
In order to elucidate the cause of treatment failure, fro-
zen EDTA plasma and blood, sampled as part of a mal-
aria immunology study, were assessed with the patient’s
consent. Species-specific PCR of the ssRNA gene con-
firmed the presence of only P. falciparum. Genotyping of
the polymorphic merozoite surface protein 2 gene (msp2)
[2] detected the same two alleles (336 bp FC27 and
487 bp IC-1 fragments) at both episodes.
Drug concentrations were measured by liquid chromatog-
raphy coupled to tandem mass-spectrometry (LC-MS/MS)in plasma collected on day 6 and 25 after initiating
artemether-lumefantrine (Figure 1). Both artemether and
dihydroartemisinin concentrations were below the limit of
detection (0.5 ng/ml) in all samples as expected because of
their very short half-lives (2–3 hrs) [3]. The lumefantrine
concentrations were 498 ng/ml on day 6 and 39.5 ng/ml
on day 25, while the metabolite desbutyl lumefantrine was
2.94 ng/ml and below detection (0.25 ng/ml), respectively.
Genotyping of drug resistance markers [4] revealed
the same profiles at both episodes; the P. falciparum
chloroquine resistance (pfcrt) 76 K allele, the multidrug
resistance 1 (pfmdr1) 86 N allele, and single copies of
the pfmdr1 gene.
Discussion
Artemether-lumefantrine is one of the most widely used
ACT for treatment of uncomplicated P. falciparum mal-
aria in sub-Saharan Africa. Previous four-dose regime
was associated with 15% treatment failure, whereas, the
now recommended six-dose regime showed, in a recent
pooled analysis, a 28-day PCR-corrected parasitological
cure rate of 97% in malaria endemic areas [5].
The effect of anti-malarial drugs in patients treated in
non-endemic areas is less studied, but can be highly
informative since patients are non-immune and not sub-
ject to re-exposure. Treatment failures with artemether-
lumefantrine have been reported in two travellers after
visiting Sierra Leone [6]and Congo [7]. Since lumefan-
trine is highly lipophilic and bioavailability depends on
concurrent food intake [8], these failures have, in the
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lated to be due to sub-optimal lumefantrine concentra-
tions. Also different sets of parasite populations have
been suggested to have caused the recurrent episodes.
Here, a late treatment failure of artemether-lumefantrine
is described in a traveller despite adequate plasma
concentrations of lumefantrine. Genotyping showed the
same msp2, pfcrt and mdr1 patterns, confirming parasite
recrudescence. Despite that the patient reported nausea
(without vomiting) and not eating the first day, the lume-
fantrine concentration (498 ng/ml) on day 6 corresponded
to what has been estimated to be sufficient to prevent re-
crudescence, i.e. day 7 concentration >280 ng/mL [8,9].
Artemether and dihydroartemisinin were, as expected due
to their short half-lives, below the level of detection on day
6. A recent publication points to desbutyl lumefantrine
possibly being a better predictor for treatment outcome
than lumefantrine [10], and the desbutyl lumefantrine con-
centration in the traveller (2.96 ng/ml) was in the same but
lower range of that in children with successful outcome
(mean 15.5 range 0.6-58.2 ng/ml). Little is known about
the pharmacokinetics of desbutyl lumefantrine and the
exact relevance of a therapeutic threshold for the metabol-
ite needs further studies.
Reduced in vivo sensitivity to artemisinin has so far
only been reported from Cambodia as reduced parasite
clearance time [11]. Reduced in vitro susceptibility to ar-
temisinin has also been described in a traveller returning
from South East Asia [12]. Here, the prompt reduction
of parasitaemia suggests good effect of artemether/
dihydroartemisinin. The late treatment failure might,
however, suggest reduced sensitivity to lumefantrine
since the concentrations were well above therapeutic
cut-off. This is further supported by the finding of pfcrt
76 K and pfmdr1 86 N alleles that have been associated
with a five-fold increase of lumefantrine inhibitory con-
centration in vitro (IC50) and also found to be selected
for after treatment with artemether-lumefantrine
in vivo in Kenya [13] and Tanzania [14]. Not finding
multiple copies of pfmdr1, also associated with reduced
sensitivity to lumefantrine, might argue against this.
However, multiple copies of pfmdr1 have only rarely
been described in Africa. In vitro susceptibility testing
could have confirmed resistance however parasites
were not available for culture.
The patient was administered several antibiotics and
paracetamol at the time of artemether-lumefantrine
treatment. Some reduced effect (higher recrudescence
rates) have been seen when co-medicated with quinine,
a drug with the same biotransformation pathway as
lumefantrine (CYP 3A4) [15]. Moreover, ciprofloxacin
which has been shown to have anti-malarial effect [16]
was administered for one week. Although the present co-
medication is not expected to have affected concentrations,interactions with other drugs might need further
investigations.
In the current, as well as previous treatment failures in
travellers, symptoms reappeared on day 14–24 after start-
ing artemether-lumefantrine, reflecting late clinical failure
[6,7]. Interestingly, the symptoms were more pronounced
and the parasite densities higher at recrudescence [7].
Although this is probably due to patients waiting longer
before seeking care (not believing it to be malaria again),
milder symptoms might have been expected considering
potential “strain-specific” immunity.
Rapid reduction of parasite biomass and symptoms to-
gether with few side effects has forwarded artemether-
lumefantrine as an attractive alternative to mefloquine
and atovaquone-proguanil for treatment of uncompli-
cated P. falciparum malaria in travellers. Although
several studies show that artemether-lumefantrine does
not have full efficacy, the drug combination has meet
WHO> 95% cure rates [1], and is recommended as six-
dose regimen in all areas irrespective of levels of drug
resistance or host immunity.
The treatment failure described here might have been
due to reduced sensitivity to lumefantrine but subopti-
mal concentrations of desbutyl lumefantrine and a
missed dose cannot be fully ruled out even if the lume-
fantrine concentrations were adequate. Drugs chosen
for treatment of P. falciparum malaria, especially in
non-immune highly vulnerable individuals such as chil-
dren and travellers, should preferably be efficacious
enough to allow for single missed doses or uneven drug
absorption. In endemic areas, partial immunity is likely
to contribute to the effect of antimalarial drugs and thus
overestimate cure rates. In line with this, decreasing ef-
fect of artemether-lumefantrine was indeed seen in an
area of decreasing malaria transmission and immunity
[17].
The present case forwards the need to further monitor
the effect of artemether-lumefantrine treatment of P.
falciparum malaria. Patients should be well informed to
seek prompt care in the event of fever the weeks after
completing artemether-lumefantrine treatment.Conflicts of interest
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